IL-27 is involved in the process of the differentiation of Th1 lymphocytes, enhancement of the cellular type immune response, and the reciprocal inhibition of Th2 humoral immune reactions.6 Evidences have demonstrated that IL-27 can inhibit tumor progression through several mechanisms, regardless of tumor immunogenicity; these characters potentially make it a valuable agent in the treatment of tumors.7 Human IL-27 is located at chromosome 16p11 and secreted as a heterodimer that consists of the Epstein–Barr-induced gene 3 (EBI3) product and p28. This evidence concerns the gene EBI3 and neoplasm.